Keros Therapeutics announced that its Board of Directors approved a new $5 million share repurchase program for its common stock. The buyback authorization follows the company's receipt of a $20 million development milestone payment from Takeda Pharmaceuticals related to the clinical trial dosing of elritercept. Keros expects its current cash reserves, including this milestone, to fund operations into 2029.
Keros Therapeutics updated its corporate presentation for use in meetings with investors and analysts. The presentation highlights the company's clinical pipeline, including rinvatercept (KER-065) for Duchenne muscular dystrophy and ALS, and elritercept for myelodysplastic syndromes.
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hematological and musculoskeletal disorders. The filing highlights ongoing Phase 2 trials for rinvatercept (KER-065) and elritercept (KER-050), the latter of which is being developed in collaboration with Takeda and Hansoh.
Keros Therapeutics reported third quarter 2026 financial results, highlighted by a net income of $14.2 million compared to a net loss in the prior year, primarily due to revenue recognition from its license agreement with Takeda. The company also announced the first patient dosed in its Phase 2 trial of rinvatercept for DMD and expects its $259.5 million cash balance to fund operations into the second half of 2028.
“We are excited to continue advancing our pipeline across both clinical and nonclinical development, building on our understanding of TGF-β biology to develop potential new treatments for patients. We remain focused on disciplined execution of our strategic priorities as we work to advance our programs and build on the potential of our pipeline.”
Jasbir S. Seehra, Ph.D., President and Chief Executive Officer